Several inhibitors of AChE, as well as N-methyl-D-aspartate (NMDA) receptor antagonists, are available currently for the treatment of Alzheimer's disease at mild and moderate stages, even though the mechanisms mediating these processes remain to be fully elucidated and sometimes theses drugs show adverse effects1. This evidence concerns the gene ACHE and Alzheimer disease.